Last reviewed · How we verify
ALT-836 in combination with gemcitabine
At a glance
| Generic name | ALT-836 in combination with gemcitabine |
|---|---|
| Sponsor | Altor BioScience |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of ALT-836 in Combination With Gemcitabine for Locally Advanced or Metastatic Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ALT-836 in combination with gemcitabine CI brief — competitive landscape report
- ALT-836 in combination with gemcitabine updates RSS · CI watch RSS
- Altor BioScience portfolio CI